Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study
New research has found that many cancer drugs recently approved in Europe lacked evidence from clinical trials that they boosted survival or quality of life.
The results of a breast cancer trial we helped fund allowed surgeons to move away from ‘radical’ mastectomies towards kinder, less invasive surgeries.
A greater understanding of the biology of mesothelioma has led to new clinical trials testing immunotherapies and targeted drugs against the disease.
In this week's news a drug was approved for some lung cancer patients in England, and vaping could be a big piece of the quitting smoking puzzle.
The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance.
Publishing national chemotherapy data has helped NHS hospitals make changes that should improve treatment
A year on from a big data report and some hospitals have changed how they discuss some aspects of treatment, including palliative care.
We go back to the 1950s to find out how one of our scientists helped transform the outlook for women with a rare cancer called choriocarcinoma.
Three quarters of the drugs previously only accessible to patients via the Cancer Drugs Fund (CDF) are now approved on the NHS.